Peptide-based PET imaging of the tumor restricted IL13RA2 biomarker
Open Access
- 24 March 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (31) , 50997-51007
Abstract
Peptide-based PET imaging of the tumor restricted IL13RA2 biomarkerKeywords
This publication has 44 references indexed in Scilit:
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell TherapyNew England Journal of Medicine, 2016
- Glioblastoma Multiforme Therapy and Mechanisms of ResistancePharmaceuticals, 2013
- 89Zr-Bevacizumab PET Imaging in Primary Breast CancerJournal of Nuclear Medicine, 2013
- A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarkerNeuro-Oncology, 2012
- EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug ResistanceCurrent Molecular Pharmacology, 2010
- Copper-64 Radiopharmaceuticals for PET Imaging of Cancer: Advances in Preclinical and Clinical ResearchCancer Biotherapy and Radiopharmaceuticals, 2009
- Peptide-based radiopharmaceuticals and cytotoxic conjugates: Potential tools against cancerCancer Treatment Reviews, 2008
- Interleukin-13 receptor–targeted nanovesicles are a potential therapy for glioblastoma multiformeMolecular Cancer Therapeutics, 2006
- Alanine-scanning Mutagenesis of α-Helix D Segment of Interleukin-13 Reveals New Functionally Important Residues of the CytokineJournal of Biological Chemistry, 2002
- Molecular Expression Analysis of Restrictive Receptor for Interleukin 13, a Brain Tumor-associated Cancer/Testis AntigenMolecular Medicine, 2000